Nanogen Issued Patent for Addressable Biologic Electrode Arrays
"Customers using biomedical diagnostic applications -- and ultimately the patients they serve -- will require increasingly sophisticated capabilities at reasonable cost," said Howard Birndorf, Nanogen chairman and chief executive officer. "Application of the technology described in this patent allows for continually increasing array densities and capabilities, which simultaneously would reduce both array cost and instrument size."
"One of the challenges in producing biologic arrays of increasing density is the integration of electronic control circuitry with each electrode on the array. The new patent describes a semiconductor-based switching technology that helps solve these scaling issues," said Dr. Michael J. Heller, co-founder of Nanogen, and currently a professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.